✦ LIBER ✦

Impact of chemotherapy regimens prior to endocrine therapy : Results from the ATAC (Anastrozole and Tamoxifen, Alone or in Combination) trial

✍ Scribed by Aman U. Buzdar; Jean-Paul Guastalla; Jean-Marc Nabholtz; Jack Cuzick; on behalf of the ATAC Trialists' Group

Publisher: John Wiley and Sons
Year: 2006
Tongue: English
Weight: 228 KB
Volume: 107
Category: Article
ISSN: 0008-543X
DOI: 10.1002/cncr.22042

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Erratum: Buzdar AU, Guastalla J-P, Nabho

Erratum: Buzdar AU, Guastalla J-P, Nabholtz J-M, et al. Impact of chemotherapy regimens prior to endocrine therapy: results from the ATAC (Anastrozole and Tamoxifen, Alone or in Combination) trial. Cancer. 2006; 107(3):472–80.

📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 58 KB

Anastrozole alone or in combination with

Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer : Results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses

✍ The ATAC (Arimidex; Tamoxifen Alone or in Combination) Trialists' Group 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 120 KB 👁 2 views

## Abstract ## BACKGROUND The first analysis of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial (median follow‐up, 33 months) demonstrated that in adjuvant endocrine therapy for postmenopausal patients with early‐stage breast cancer, anastrozole was superior to tamoxifen in terms of d